Newron Pharmaceuticals SpA, the Italian biopharmaceutical company, is to acquire Hunter-Fleming Ltd., a privately-held British company focused on neurodegenerative and inflammatory disorders, in an all-share transaction.
Small and medium-sized companies (SMEs) that have done preclinical work on developing advanced therapies, such as gene or cell products, will be eligible to receive a certificate from the European Medicines Agency (EMEA) verifying that their preclinical data package meets European regulatory standards for quality and safety.
4SC AG, which has developed a computer-based technology for screening drug candidates, has entered into a research collaboration with the Wuppertal-based company, AiCuris GmbH, to investigate anti-infective drug candidates.
CeNeS Pharmaceuticals Plc said it is in discussions which may or may not lead to an offer for the company.
GE Healthcare, the medical diagnostics unit of General Electric Co. of the US, has made a cash offer for all the shares of Whatman Plc, a British supplier of filters and membranes for laboratory research.
A committee of the House of Commons has raised questions about the Labour government’s commitment to a proposed new medical centre for central London following the disclosure that the Treasury has clawed back £92 million from savings accumulated by the Medical Research Council for financing the project.
A proposal to create a single jurisdiction for the litigation of patent disputes in the European Union is gathering political support.
Exiqon A/S, a Danish supplier of gene expression analysis products, has disclosed details of its planned acquisition of Oncotech Inc., a privately-held US company that develops and sells diagnostic tests to optimise treatments for cancer patients.
Stem Cell Sciences Plc (SCS) has entered into a collaboration agreement with the Myelin Repair Foundation (MRF) of Saratoga, California, to produce specific types of human brain cells from stem cell lines derived from foetal tissue.
Ipsen SA of France has signed a memorandum of understanding with The Salk Institute in La Jolla, California, to carry out basic research on proliferative and degenerative diseases.